Nykode Therapeutics As (VACBF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nykode Therapeutics Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.904 -- 00:00:07.272 Greetings and welcome to the NICO Therapeutics Q4 2025 financial results 00:00:07.272 -- 00:00:12.380 presentation. At this time, all participants are in listen-only mode. 00:00:12.380 -- 00:00:16.387 A question and answer session will follow the formal presentation and you may ask a question 00:00:16.387 -- 00:00:19.692 at any time by typing it into the ask a question feature on your screen. 00:00:19.692 -- 00:00:22.536 As a reminder, this conference is being recorded. 00:00:22.536 -- 00:00:27.304 It's now my pleasure to introduce Chief Executive Officer Michael Ensign. 00:00:27.304 -- 00:00:29.528 Please go ahead, sir. 00:00:29.528 -- 00:00:34.173 Thank you very much, Kevin, and a very warm welcome to all participants at this quarterly 00:00:34.173 -- 00:00:38.658 presentation from NICODE, where we look forward to take you through the fourth quarter 00:00:38.658 -- 00:00:42.402 and achievements happening subsequent to the quarter. 00:00:42.402 -- 00:00:47.028 Just a quick reminder before we start of the forward-looking statement. 00:00:47.028 -- 00:00:51.092 We assume you are all familiar with these statements and that notice will move forward. 00:00:51.092 -- 00:00:55.577 Happy to, again, have with me here today in the room Aonita Frederiksen, our co-founder 00:00:55.577 -- 00:00:58.486 and chief scientific officer in health and business development. 00:00:58.486 -- 00:01:04.032 who will take us through a deeper dive on our status for the NEO program 00:01:04.032 -- 00:01:08.938 and our tolerance program, as well as Harald Guggen, our CFO, who will take you through 00:01:08.938 -- 00:01:13.323 the financial data towards the end of the presentation. 00:01:13.323 -- 00:01:17.749 Again, as a sort of recap, reminding everybody of ou...